xNOS

xNOS is a biotechnology company that specializes in developing a multi-target therapeutic compound for treatment of sexual dysfunction in both women and men with type 1 and type 2 diabetes mellitus. The company was founded in 2016 and today has developed a novel target drug candidate Xoin® (xNOSniox). xNOS's comprehensive molecular expertise is expected to lead to a stream of future innovative commercial products. Nitric oxide technology is a key focus of xNOS's strategy. xNOS's technology base consists of validated and proprietary next-generation endothelial nitric oxide synthase (eNOS) activator therapies.